Welcome to our dedicated page for Alimera Sciences news (Ticker: ALIM), a resource for investors and traders seeking the latest updates and insights on Alimera Sciences stock.
Alimera Sciences, Inc. (NASDAQ: ALIM) is a leading global pharmaceutical company committed to advancing retinal health. Founded in June 2003, the company specializes in the research, development, and commercialization of prescription ophthalmic pharmaceuticals. Alimera's primary focus is on diseases affecting the retina, particularly those that are not well managed by current therapies. The company's flagship product, ILUVIEN, is a sustained-release intravitreal implant used for the treatment of diabetic macular edema (DME) and non-infectious uveitis affecting the posterior segment of the eye (NIU-PS) outside the U.S.
ILUVIEN utilizes CONTINUOUS MICRODOSING™ technology, releasing sub-microgram levels of fluocinolone acetonide, a corticosteroid, for up to 36 months. This technology helps to reduce disease recurrence, thereby enabling patients to maintain vision longer with fewer injections. ILUVIEN is approved in the U.S. and multiple international markets, including 17 European countries, China, and regions in the Middle East.
Recently, Alimera announced positive data from several clinical studies, such as the PALADIN study, which evaluated the long-term safety of ILUVIEN in treating DME. The company also made headlines by completing enrollment for the Synchronicity Study, focusing on YUTIQ, another fluocinolone acetonide intravitreal implant for chronic non-infectious uveitis.
Moreover, Alimera continues to expand its executive team to strengthen its financial and operational capabilities. Elliot Maltz, C.P.A., has been named as the new Chief Financial Officer to drive growth and improve cash flow. The company's European operations are managed through its subsidiary, Alimera Sciences Limited, based in London.
Financially, Alimera Sciences has shown robust growth. In Q4 2023, the company reported net revenues of $26.3 million, an 88% increase compared to the same period in 2022. For the full year 2023, net revenues were up 49% to $80.8 million. This growth is a testament to the successful commercialization of ILUVIEN and YUTIQ.
Looking ahead, Alimera aims to further its mission of being invaluable to patients, physicians, and partners concerned with retinal health. The company is actively involved in numerous clinical studies and regulatory efforts to expand the therapeutic indications for its products, ensuring continued innovation and improved patient outcomes.
For more information, please visit www.alimerasciences.com.
Alimera Sciences (Nasdaq: ALIM) reported a consolidated net revenue of $14 million for Q4 2021, marking a 15% increase from Q3 2021 and a 1% rise compared to Q4 2020. For the full year 2021, revenues reached $59 million, up 16% year-over-year. The U.S. segment exhibited notable growth, with a 20% sequential increase in Q4. International revenue faced challenges, decreasing 13% due to COVID-19 restrictions. The company experienced a net loss of $4.1 million in Q4 2021, widening from $1.0 million in Q4 2020, although the annual net loss improved to $4.4 million from $5.3 million. Cash reserves increased to $16.5 million.
Alimera Sciences announced the publication of the 3-year results from the PALADIN study in the journal Ophthalmology, showing significant improvements in visual acuity and reduced treatment burden for patients with diabetic macular edema (DME) receiving ILUVIEN. Key findings include a 70.5% treatment reduction, with only 2.97% requiring surgery for intraocular pressure (IOP) issues. The study supports earlier ILUVIEN use for better outcomes. The results confirm the mitigation of side effects when following the U.S. FDA label.
Alimera Sciences (Nasdaq: ALIM) will report Q4 and full-year 2021 financial results on February 24, 2022, before market open. A conference call will be held at 9:00 AM ET to discuss the results and corporate updates. Pre-registration is encouraged for a smoother experience, while alternative dial-in options are available for those unable to register online. The call will also be accessible via a live webcast. A replay of the call will be available for a limited time following the event.
Alimera Sciences announced the pricing approval for ILUVIEN for the treatment of non-infectious posterior uveitis in Spain, marking its third major market for this indication. The approval allows Brill Pharma to launch ILUVIEN, a sustained release intravitreal implant designed to reduce symptoms for up to 36 months. With this launch, ILUVIEN continues to establish its presence in Europe, following previous approvals in Germany and the U.K. Alimera aims to enhance patient care in retinal health, addressing a significant need for effective treatments for chronic inflammatory eye diseases.
Alimera Sciences (Nasdaq: ALIM) announced that CEO Rick Eiswirth will present at the MicroCap Rodeo Winter Wonderland Best Ideas Virtual Investor Conference from February 8-11, 2022. His presentation is scheduled for February 9 at 10:00 AM ET. Additionally, Eiswirth and CFO Phil Jones will hold one-on-one meetings with investors on February 10-11. Alimera focuses on retinal health and aims to enhance patients' vision longevity. For more details, visit www.alimerasciences.com.
Alimera Sciences (Nasdaq: ALIM) has announced that Rick Eiswirth, President and CEO, will participate in two significant investor conferences in January 2022. He will present at the H.C. Wainwright BioConnect 2022 Virtual Conference, with a pre-recorded session available from January 10 to January 13, 2022. Additionally, he will host one-on-one meetings at the Bio One-on-One Partnering @ JPM event, scheduled for January 10-14, 2022. Alimera focuses on enhancing retinal health and vision longevity for patients and partners.
Alimera Sciences, Inc. (Nasdaq: ALIM) appointed Erin Parsons to its Board of Directors, enhancing its strategic initiatives in retinal health. With over 20 years in the ophthalmic industry, Parsons brings substantial experience in scientific strategy and medical communications, particularly within the retina space. CEO Rick Eiswirth emphasized the value of her industry relationships and expertise in increasing advocacy for ILUVIEN, a treatment for retinal diseases. Parsons founded Parsons Medical Communications and has been pivotal in launching numerous retinal therapies.
Alimera Sciences (Nasdaq: ALIM) announces that CEO Rick Eiswirth will participate in three investor conferences in November 2021, aimed at enhancing engagement with shareholders. His key presentation will occur at the Q4 Investor Summit on November 16-17, 2021, at 9:30 AM ET, offering one-on-one meeting opportunities. Additionally, he will engage in video conferencing at the Alliance Global Partners Virtual Biotech & Specialty Pharma Conference on November 10, and the Craig-Hallum Alpha Select Conference on November 16. For more details, visit Alimera's website.
Alimera Sciences (Nasdaq: ALIM) reported third quarter 2021 net revenue of approximately $12.2 million, a 2% decrease year-over-year but a 14% increase compared to the second quarter of 2021. Notably, U.S. end-user demand surged 15% compared to both Q3 2020 and Q2 2021. Operating expenses rose to approximately $12.5 million, reflecting new investments in brand awareness following COVID-19 challenges. The Q3 net loss was $(4.2) million, with a basic net loss per share of approximately $(0.60). Cash reserves decreased to $21.5 million as of September 30, 2021.
Alimera Sciences, Inc. (Nasdaq: ALIM) will announce its third quarter 2021 financial results on October 28, 2021, prior to market open. The management will hold a conference call at 9:00 AM ET on the same day to discuss the financial results and provide corporate updates. Participants are encouraged to pre-register for the call to receive their dial-in numbers. A live webcast will also be available, along with replay options for later access. Alimera aims to support retinal health and better vision for its stakeholders.
FAQ
What is the current stock price of Alimera Sciences (ALIM)?
What is the market cap of Alimera Sciences (ALIM)?
What is Alimera Sciences, Inc. specialized in?
What is ILUVIEN?
Where is Alimera Sciences headquartered?
What are the latest financial results for Alimera Sciences?
Who is the new Chief Financial Officer of Alimera Sciences?
What recent clinical studies has Alimera Sciences completed?
In which regions is ILUVIEN approved?
What is the mission of Alimera Sciences?
What technology does ILUVIEN utilize?
Where can I find more information about Alimera Sciences?
